Kevin D. Shenk
YOU?
Author Swipe
View article: Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. C…
View article: Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Supplementary Figures S1-S4; Supplementary Tables S1-S2.
View article: Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Supplementary Figures S1-S4; Supplementary Tables S1-S2.
View article: Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. C…
View article: Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. He…
View article: Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
View article: Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
View article: Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
View article: Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
View article: Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Open
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. He…